• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Inspiration Biopharmaceuticals

edit

Inspiration Biopharmaceuticals, Inc. develops recombinant blood coagulation factor products for the treatment of hemophilia. Its product candidates include IB1001, an intravenous recombinant factor IX for the acute and preventative treatment of bleeding in individuals with hemophilia B; and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) for the treatment of individuals who have developed inhibitors against human FVIII and for individuals with acquired hemophilia A. The company also has preclinical programs that focus on human recombinant factor VIIa for individuals with either hemophilia A or B who have developed inhibitors, and individuals with factor VII deficiency; human recombinant FVIII to treat individuals with hemophilia A. Inspiration Biopharmaceuticals has a strategic partnership with Ipsen SA. The company was founded in 2004 and is based in Laguna Niguel, California.

Milestones

edit

• 
  Inspiration Biopharmaceuticals added Gordon Busenbark as Senior Vice President and CFO.
  Posted 10/3/11 at 10:06pm
• 
  Inspiration Biopharmaceuticals added Andrew Grethlein as Executive Vice President and COO.
  Posted 10/3/11 at 10:06pm
• 
  Inspiration Biopharmaceuticals added Michael Griffith as President and CEO.
  Posted 10/3/11 at 10:06pm
• 
  Inspiration Biopharmaceuticals — Inspiration nabs $35M milestone on EMA hemophilia review (10/3/11)
  Posted 10/3/11 at 10:07pm via fiercebiotech.com

Videos

Screenshots

edit

Sources

Inspiration nabs $35M milestone on EMA hemophilia review (fiercebiotech.com) [edit]